

Advanced Therapy Showcase in Tokyo #2

The Partnering Event in Tokyo Calls for Live-Streaming Presenters



Summary

Life Science Innovation Network Japan (LINK-J) boldly launched the partnering event series "Advanced Therapy Showcase in Tokyo (ATST)" with its first edition successfully held back in January 2021. Now we are pleased to announce that the second edition of the series, the ATST#2, is going to be held on Friday, January 28, 2022.

The ATST#2 features live-streaming company presentations and pre-arranged 1-on-1 business partnering Meetings.

The event will be fully virtual. Any entities or individuals engaged in the field of advanced therapy including but not limited to cell & gene therapy, regenerative medicine, nucleic acid therapy, etc., are encouraged to participate in this event to find suitable and relevant partner candidates for their business endeavors.

Event Outline

Date	Friday, January 28, 2022, JST
Format	Virtual
Program	Under construction
Official Language	English
Contact	atst@link-j.org
Sponsor Organizer	LINK-J
Registration/Application	https://atst220128.peatix.com



Held in Combination with "The 6th Industry Academic Government Symposium on Regenerative Medicine"

Target Groups for Company Presenters

Product developers, novel technology providers, platform developers, and researchers who seek partners in Japan or elsewhere, and crave to excel in the field of advanced therapies such as:

- ✓ regenerative medicine and tissue engineering,
- ✓ cell therapy and gene-modified cell therapy,
- ✓ gene therapy (in vivo/ex vivo) and gene editing therapy,
- ✓ exosome-based therapy,
- ✓ nucleic acid medicine,

Registration & Application

	Registration tiers	Registration fee	Registration deadline
Live-streaming company presenters	<ul style="list-style-type: none">✓ Entitled to give a virtual live-streaming presentation for 20~25min (time is subject to change depending on the number of entries). <i>In case the number of applicants exceeds the capacity, the organizing committee may ask a certain number of applicants to wait for the next occasion.</i>✓ Entitled to one-on-one business meeting arrangements, and✓ Entitled to access the live-streaming presentations.	20,000JPY /organization 10,000JPY /LINK-J member <i>Discount rate (15,000 JPY/organization) will be applied for those who present the discount code, which will be given to supporting organizations to distribute among its members</i>	Friday, December 10, 2021, JST

General Attendees

We plan to open registration site for general attendees in November (free of charge). If you are interested in participating as a general attendee at this stage, give us a note at atst@link-j.org. You will be notified individually when the site opens.

* Registration/application website is <https://atst210128.peatix.com>

* Non-confidentiality : Any information disclosed in live-streaming presentations shall be regarded as non-confidential.

Summary on the Previous Edition

Company presentation speakers at the ATST#1

- BrainXell, Inc. ; Shouming Du (USA)
- Exopharm Ltd. ; Chris Baldwin, PhD (Australia)
- TerumoBCT, Inc. ; Jun Tanaka (Japan)
- Helixmith Co., Ltd. ; Sunyoung Kim, PhD (ROK)
- Eyestem Research Pvt. Ltd. ; Jigin Desai (India)
- CellProthera Pte. Ltd. Singapore ; Alexandre Civiere (Singapore)
- Biomaster Inc. ; Takuji Hasegawa (Japan)
- Fraunhofer Institute for Cell Therapy and Immunology (IZI) ; Thomas Tradler (Germany)
- Salipro Biotech AB ; Maria Knudsen, PhD (Sweden)
- PDC*line pharma SA ; Eric Halioua, MS, MBA (Belgium)
- TreeFrog Therapeutics SAS ; Maxime Feyeux, PhD (France)
- Glycostem Therapeutics B.V. ; Troels Jordansen (Netherlands)

On-demand exhibitors at the ATST#1

- Q-Gen Cell Therapeutics (Australia)
- Immusoft Corporation(USA)
- Nippon Boehringer Ingelheim Co., Ltd. (Japan)
- Biogelx Ltd. (UK)
- The Isthmus Foundation (USA)
- ORGANOIDSCIENCES Ltd. (ROK)
- Inner Resource, Inc. (Japan)

Participating companies at the ATST#1

4Bio Capital	CMPlus	Helixmith Co., Ltd.
ACCERISE, Inc.	Cyfuse Biomedical	Hitachi Global Life Solutions, Inc.
aceRNA Technologies, Co., Ltd.	Cytori Therapeutics Inc.	Hokkaido University
ActualEyes Inc.	D3 LLC	Ibaraki Prefectural Government
Ajinomoto Co., Inc.	Daiichi Sankyo Co., Ltd.	iBody inc.
Alliance for Regenerative Medicine (ARM)	Digital Garage, Inc.	Immusoft Corporation
ARTWORKS Inc.	DyDo Pharma, Inc.	Information Services International-Dentsu, Ltd.
Asahi Kasei Pharma Corporation	Eil Inc.	Inner Resource
Aspect Biosystems Ltd.	Eli Lilly	Inno BioScience Co., Ltd.
Astellas Pharma Inc.	Elixirgen Scientific, Inc.	Isthmus Foundation
Axil Capital Advisors K.K.	ENEOS	Japan Agency for Medical Research and Development
Biogelx Ltd.	Eurotechnology Japan K.K.	Japan Blood Products Organization
Biomaster Inc.	Exopharm Ltd.	Japan External Trade Organization (JETRO)
BioSket / BioWire	Eyestem Research Pvt. Ltd.	Japan Medical Publisher
BrainXell, Inc.	Forum for Innovative Regenerative Medicine (FIRM)	JCR Pharmaceuticals
Cambridge Consultants	Fraunhofer Institute for Cell Therapy and Immunology (IZI)	JGC Holdings Corporation
Cardiff University	Frontier Management Inc.	Johnson and Johnson Innovation
Cell and Gene Therapy Catapult	Fuji Chemical Industries Co., Ltd.	JPRO/Western University
CellGenTech, Inc.	Fujimi Venture Partners Ltd.	JSR Corporation
Cellino	Fujinokuni Medical Castle Town	JW CreaGene
CellProthera Pte. Ltd. Singapore	Promotion Organization Pharma	
CellSeed Inc.	Valley Center	
Century Medical, Inc.	General Prognostics, Inc. (GPx)	
CHARTAE Consulting, LLC.	Global Life Sciences Technologies	
Chugai Pharmaceutical Co., Ltd.	Japan	
City of Yokohama	Glycostem Therapeutics B.V.	
CMIC Holdings Co., Ltd.		

Participating companies at the ATST#1

KAHM Japan Ltd.	NEC Corp.	Shinsei Capital Partners, Ltd.
KAKEHASHI Inc.	NejoScience Co., Ltd.	Shirakawa Life Research
Kawasaki City	Nippon Boehringer Ingelheim Co.,Ltd	Showa Denko Materials Co., Ltd.
Keio University	Nippon Shinyaku Co., Ltd.	SIGMAXYZ Inc.
Kirin Holdings Company, Limited	Nobelpharma Co., Ltd.	SOUSEIKAI Global Clinical Research Center
Komazawa University	NOF Corporation	Spiber Inc.
Kowa Co., Ltd.	Organization for Small & Medium Enterprises and Regional Innovation, Sumitomo Dainippon Pharma Co., Ltd.	S-RACMO Co., Ltd.
Kuraray Co., Ltd.	JAPAN	Taiho Innovations, LLC
Kureha Corporation	ORGANOIDSCIENCES Ltd.	Takeda Pharmaceutical Co., Ltd.
Kyowa Kirin Co., Ltd.	Otsuka Pharmaceutical Co., Ltd.	Tanaka Kikinzoku Kogyo K.K.
Kyushu University Hospital	Otsuka Pharmaceutical Factory, Inc.	Temari, Inc.
Life Science Institute, Inc.	PDC*line pharma SA	TerumoBCT, Inc.
Marubeni Corporation	Perseus proteomics, Inc.	Tohoku University
MATRIXOME, Inc.	Pfizer Japan Inc.	Tokyo Medical and Dental University
Medical & Biological Laboratories Co., Ltd.	Pharma Business Academy Ltd.	TreeFrog Therapeutics SAS
MediGear International Corporation	PuREC Co., Ltd.	U.S. Embassy, Tokyo
MEDINET Co., Ltd.	Q-Gen Cell Therapeutics	University of Rochester Medical Center
Megakaryon Corporation	Queen Mary University of London (QMUL)	University of Yamanashi
Metcela Inc.	Rainbow BioScience, LLC	VectorBuilder Japan
miibio, Inc.	Remiges Ventures, KK	WillNet
Mitsubishi Corporation	RICOH Co., Ltd.	Xsphera Biosciences Inc.
Mitsubishi Research Institute	RIKEN (Institute of Physical and Chemical Research)	
Mitsubishi Tanabe Pharma Corporation	ROHTO Pharmaceutical Co., Ltd.	
Mitsui Chemicals, Inc.	RoslinCT Ltd.	
Mizuho Bank, Ltd.	Salipro Biotech AB	
Mochida Pharmaceutical Co., Ltd.	SanBio Co., Ltd.	
Modalis Therapeutics Corporation	National Center for Child Health and Development	
Nagano Science Co., Ltd.	Santen Pharmaceutical Co., Ltd.	
National Center for Child Health and Development	ShiftZero K.K.	
National Institute of Health Sciences	Shimadzu Corp.	

Backgrounds of attendees at the ATST#1

